• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

One size doesn’t fit all, when using hormone therapy to treat endometriosis

Bioengineer by Bioengineer
October 25, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Endometriosis — a condition caused by uterine tissue growing outside of the organ — affects 10% of reproductive-aged women, whom it causes chronic pain that is significant and debilitating. The standard first-line treatment for all women with endometriosis is hormonal, specifically progestin-based, therapy.

Yet a team of researchers at Yale has shown that the effectiveness of progestin-therapy depends on whether a woman's endometriotic lesions have the progesterone receptor (PR) present. This study appears online in the Journal of Clinical Endocrinology & Metabolism.

The researchers tested the endometriotic lesions of 52 women who had undergone surgical evaluation for endometriosis at Yale New Haven Hospital for their PR status. They found a significant association between PR status and responsiveness to progestin-therapy. Those whose endometriotic lesions were PR-positive responded much better to the progestin-therapy, while those whose lesions were PR-negative found little relief from progestin-therapy alone.

From these findings, the research team concluded that knowing a woman's PR-status may help them develop a "novel, targeted, precision-based" approach to treating and managing endometriosis individually. "Receptor status in endometriosis could be used in a manner analogous to the use of estrogen/progesterone receptor status in breast cancer for tailoring hormonal-based regimens," said Dr. Valerie Flores, first author and clinical instructor at the Yale School of Medicine.

"Such an approach to endometriosis management would make trialing progestin-based therapy to determine response unnecessary," said Flores, "and would therefore minimize delays in providing the optimal medical therapy for each individual patient."

###

This study was funded by a grant from the National Institutes of Health. Other authors on this study include Arne Vanhie, Tran Dang, and Hugh Taylor.

Media Contact

Kendall Teare
[email protected]
203-836-4226
@yale

http://www.yale.edu

https://academic.oup.com/jcem/advance-article/doi/10.1210/jc.2018-01227/5139742

Related Journal Article

http://dx.doi.org/10.1210/jc.2018-01227

Share12Tweet7Share2ShareShareShare1

Related Posts

Real-World Insights on Biologic Treatment Adherence

November 2, 2025

Comparing Glucose Monitoring Methods for Diabetes Care

November 2, 2025

Assessing Psychological First Aid Training in Disaster Nursing

November 2, 2025

Modeling Soft Tissue Deformation for Prosthetic Sockets

November 2, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1295 shares
    Share 517 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    203 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    137 shares
    Share 55 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Immune Checkpoint Inhibition Shifts Failure Patterns in Lung Cancer

Real-World Insights on Biologic Treatment Adherence

Comparing Glucose Monitoring Methods for Diabetes Care

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.